cancers-logo

Journal Browser

Journal Browser

Ablation Treatment for Malignant Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 September 2026 | Viewed by 786

Special Issue Editors


E-Mail Website
Guest Editor
Department of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands
Interests: interventional radiology; colorectal cancer; liver metastases; colorectal liver metastases; thermal ablation

E-Mail Website
Guest Editor
Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands
Interests: interventional oncology; pancreatic ductal adenocarcinoma; irreversible electroporation; stereotactic ablative radiotherapy; immunotherapy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands
Interests: oncology; radiology; nuclear medicine; medical imaging

Special Issue Information

Dear Colleagues,

Image-guided ablation techniques have emerged as an increasingly important treatment modality for a wide range of malignant tumors. Radiofrequency ablation, microwave ablation, cryoablation, and other non-thermal techniques are now being integrated into multidisciplinary oncological care, offering minimally invasive alternatives or complementary options to surgery, systemic therapy, and radiotherapy. Advances in imaging guidance, ablation technology, and peri-procedural patient management have significantly improved safety, efficacy, and oncological outcomes. Moreover, ongoing research explores novel indications, combination strategies with immunotherapy, and the role of ablation in oligometastatic disease. This Special Issue aims to highlight recent progress, clinical applications, and future perspectives of ablation treatment for both primary and metastatic malignancies across different organ systems. We welcome original research, reviews, and technical reports that provide new insights into optimizing ablation strategies, patient selection, and long-term outcomes.

Dr. Madelon Dijkstra
Prof. Dr. Martijn Meijerink
Dr. Susan Van Der Lei
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ablative therapies
  • thermal ablation
  • image-guided therapy
  • minimally invasive
  • radiofrequency ablation (RFA)
  • microwave ablation (MWA)
  • cryoablation
  • irreversible electroporation (IRE)
  • malignant tumors
  • oligometastatic disease
  • immunotherapy combinations
  • interventional oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 383 KB  
Article
Toxicity of Ablative Radiation Therapy in the Management of Patients with Child-Pugh B/C Liver Function and Unresectable Hepatocellular Carcinoma (HCC)
by William Sperduto, Taofik Oyekunle, Donna Niedzwiecki, Christine E. Eyler, Brian Czito, Christopher G. Willett, Devon Godfrey, Joseph K. Salama, Manisha Palta and Sarah J. Stephens
Cancers 2026, 18(4), 681; https://doi.org/10.3390/cancers18040681 - 19 Feb 2026
Viewed by 509
Abstract
Background/Objectives: Hypofractionated ablative radiation is an increasingly popular option for patients with hepatocellular carcinoma (HCC). However, concern remains about the risk for radiation-induced liver toxicity in patients with decompensated liver function. Methods: We retrospectively identified patients with underlying Child-Pugh (CP) B or C [...] Read more.
Background/Objectives: Hypofractionated ablative radiation is an increasingly popular option for patients with hepatocellular carcinoma (HCC). However, concern remains about the risk for radiation-induced liver toxicity in patients with decompensated liver function. Methods: We retrospectively identified patients with underlying Child-Pugh (CP) B or C liver function treated at our University and Veterans Affairs (VA) departments from 2014 to 2019. Primary endpoints included treatment-related toxicity and dosimetric parameters. Results: 38 patients were included in the analysis. Most patients (98%) had CP B or Albumin-Bilirubin (ALBI) grade 2–3 (100%) liver disease. The median dose was 50 Gy (range 30–50) delivered in 5 or 10 fractions. Most patients had a single tumor treated (66%) with a median size of 3.1 cm (Interquartile Range (IQR) 2.3–4.1). The mean liver dose was 9.28 Gy (IQR 6.76–13.64) with a liver D800cc of 3.99 Gy (IQR 1.41–8.02). All patients completed their intended course with a median follow-up of 43 months. Four patients (10.3%) developed non-classical radiation-induced liver disease (RILD), comparable to the rate for patients with CP A function treated contemporaneously (8.3%). Otherwise, one patient (2.6%) experienced acute grade 3+ (non-RILD) hepatobiliary toxicity, while one patient (2.6%) experienced late grade 3+ hepatobiliary toxicity. Local control was promising with 2-year freedom from progression in the treated lesion of 73% (95% CI 38–91%). Median overall survival was 12 months (95% CI 5–25 months). Conclusions: Ablative radiation for patients with decompensated liver function and HCC appears well tolerated with low rates of RILD and encouraging local control. With careful selection, these patients should be considered for inclusion in future randomized trials. Full article
(This article belongs to the Special Issue Ablation Treatment for Malignant Tumors)
Show Figures

Figure 1

Back to TopTop